$105.99
Out of stock
Availability: Ships today if ordered and paid by 12 PM PST
ACE-083 is a novel myostatin inhibitor still in clinical trials for treating muscle atrophy and weakness. Developed by Acceleron Pharma, it works by inhibiting myostatin, a protein that impedes muscle growth.
ACE-083 is an investigational drug that has entered Phase 2 trials for conditions like Charcot-Marie-Tooth, inclusion body myositis, and post-stroke rehabilitation. It offers promise for building muscle mass in sarcopenia, aging, bed rest, and people with neuromuscular diseases.
The mechanism of ACE-083 focuses on binding to the activin type II receptor, preventing myostatin activation. Myostatin normally binds to activin receptors, initiating a cell signaling cascade that inhibits muscle protein synthesis. ACE-083 blocks this interaction, allowing greater skeletal muscle hypertrophy.
Animal studies showed it could increase muscle mass by up to 33% in mice. For humans, it may provide targeted muscle growth in weakened, atrophied areas without affecting healthy muscle tissue.
ACE-083 has entered Phase 2 trials after successfully completing Phase 1 without safety concerns. The current efficacy studies target treating muscle loss in Charcot-Marie-Tooth disease, sporadic inclusion body myositis, and post-stroke weakness.
Phase 1 results demonstrated increased muscle volume in the tibialis anterior. Ongoing Phase 2 studies are further evaluating changes in muscle strength and motor function. If successful, Acceleron aims to expand into additional Phase 2 trials assessing other muscle-wasting disorders.
If approved, ACE-083 could aid conditions involving involuntary muscle loss like aging, illness, injury, and immobility. It may help rebuild strength in weak, atrophied muscles without spreading effects to normal muscles. Bodybuilders seek it for targeted muscle growth potential. But effects may be localized rather than bodywide. More evidence is needed to rate effectiveness since human trials are still ongoing.
Research indicates ACE-083 may be beneficial for:
More evidence is still needed to confirm effectiveness and long-term safety.
In clinical trials, the adverse effects of ACE-083 have so far been mild. Phase 1 reported common side effects of muscle pain, injection site reactions, numbness, and increases in liver enzymes.
These were temporary and not serious. Still, as research continues, other risks could emerge. Long-term safety is not yet characterized. ACE-083 remains an experimental drug pending more research on efficacy and adverse effects.
ACE-083 is supplied as a sterile, lyophilized powder. Vials contain 2, 4, or 8 mg to be reconstituted with bacteriostatic water for injection. Dosages in trials ranged from 150 to 200 mg. Administration is via intramuscular injection into targeted muscles.
The onset of action occurs within 4-6 weeks based on Phase 1 data, with benefits lasting up to 3 months from a single dose. Ongoing Phase 2 results will further inform optimal clinical dosing.
As an investigational drug, ACE-083 is not currently approved or available. Purchasing peptides online claiming to be ACE-083 is ill-advised. The validity and quality of such products are unlikely to match pharma-grade materials used in clinical trials. Be wary of any retailer offering ACE-083 for sale before the completion of Acceleron’s development and approval process.
